2. Search Result
Search Result
Results for "

rapamycin

" in MedChemExpress (MCE) Product Catalog:

70

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

2

Peptides

6

Natural
Products

1

Recombinant Proteins

6

Isotope-Labeled Compounds

7

Antibodies

2

Click Chemistry

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10219
    Rapamycin
    1335+ Cited Publications

    Sirolimus; AY-22989; NSC 226080

    		 mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-10218
    Everolimus
    110+ Cited Publications

    RAD001; SDZ-RAD

    		 mTOR FKBP Autophagy Apoptosis Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus
  • HY-111373
    RapaLink-1
    10+ Cited Publications

    		 mTOR Autophagy Cancer
    RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
    RapaLink-1
  • HY-P1122
    Cyclosporin H
    3 Publications Verification

    		 Formyl Peptide Receptor (FPR) Infection Inflammation/Immunology
    Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.
    Cyclosporin H
  • HY-153806
    RapaBlock

    ZZY05-092

    		 FKBP Cancer
    RapaBlock is a potent, non-immunosuppressive and brain-impermeable FKBP12 ligand .
    RapaBlock
  • HY-124798
    Rheb inhibitor NR1
    3 Publications Verification

    		 mTOR Neurological Disease Inflammation/Immunology Cancer
    Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven T389pS6K1 and increases the phosphorylation of S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity .
    (Rheb-IVK: Rheb-dependent mTORC1 kinase activity)
    Rheb inhibitor NR1
  • HY-101920
    Autophinib
    10+ Cited Publications

    		 Autophagy PI3K Neurological Disease Cancer
    Autophinib is a potent, selective autophagy inhibitor with IC50s of 90 nM and 40 nM for starvation- and Rapamycin-induced autophagy, respectively. Autophinib is also an ATP competitive Vacuolar Protein Sorting 34 (VPS34) inhibitor with an IC50 of 19 nM. Autophinib inhibits autophagy induced by starvation or Rapamycin by targeting VPS34 .
    Autophinib
  • HY-134904
    RMC-6272
    3 Publications Verification

    RM-006

    		 mTOR Cancer
    RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors .
    RMC-6272
  • HY-130835
    FKBP12 PROTAC RC32

    RC32

    		 PROTACs FKBP Cancer
    FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .
    FKBP12 PROTAC RC32
  • HY-12424
    Zotarolimus
    4 Publications Verification

    ABT-578; A 179578

    		 Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .
    Zotarolimus
  • HY-136660
    PQR626

    		mTOR Neurological Disease
    PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders .
    PQR626
  • HY-10219R
    Rapamycin (Standard)

    Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)

    		 Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (Standard)
  • HY-10219S
    Rapamycin-d3
    1 Publications Verification

    Sirolimus-d3; AY-22989-d3; NSC 226080-d3

    		 Isotope-Labeled Compounds mTOR FKBP Autophagy Cancer
    Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-d3
  • HY-10218S
    Everolimus-d4

    RAD001-d4; SDZ-RAD-d4

    		 mTOR FKBP Autophagy Apoptosis Cancer
    Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-d4
  • HY-136265
    BC-LI-0186
    1 Publications Verification

    		 Aminoacyl-tRNA Synthetase Cancer
    BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .
    BC-LI-0186
  • HY-19555A
    Seco Rapamycin sodium salt

    Secorapamycin A monosodium

    		 Drug Metabolite Others
    Seco Rapamycin sodium salt is the ring-opened product of Rapamycin. Seco-rapamycin is reported not to affect the mTOR function.
    Seco Rapamycin sodium salt
  • HY-12424A
    42-(2-Tetrazolyl)rapamycin

    		Drug Intermediate Cancer
    42-(2-Tetrazolyl)rapamycin is a proagent compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.
    42-(2-Tetrazolyl)rapamycin
  • HY-N0381
    Maackiain
    1 Publications Verification

    DL-​Maackiain

    		 Keap1-Nrf2 p38 MAPK NOD-like Receptor (NLR) NF-κB mTOR Monoamine Oxidase Nuclear Factor of activated T Cells (NFAT) PKC Apoptosis Pyroptosis Autophagy Dengue Virus Infection Neurological Disease Metabolic Disease
    Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever 。
    Maackiain
  • HY-10219G
    Rapamycin

    Sirolimus; AY-22989; NSC 226080

    		 mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Infection Cancer
    Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-10219GL
    Rapamycin (GMP Like)

    Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

    		 mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (GMP Like)
  • HY-10219S1
    Rapamycin-13C,d3

    Sirolimus-13C,d3; AY-22989-13C,d3 NSC 226080-13C,d3

    		 Isotope-Labeled Compounds mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin- 13C,d3 (Sirolimus- 13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3
  • HY-123691
    7-O-Demethyl rapamycin

    		Fungal Infection Inflammation/Immunology Cancer
    7-O-Demethyl rapamycin, a derivative of Rapamycin (HY-10219), has antifungal activity and immunosuppressant properties. 7-O-Demethyl rapamycin has useful tumor cell growth-inhibiting activity .
    7-O-Demethyl rapamycin
  • HY-10949
    SMER3

    		E1/E2/E3 Enzyme Cancer
    SMER3, a Rapamycin enhancer, is a selective Skp1-Cullin-F-box (SCF) Met30 ubiquitin ligase inhibitor. SMER3 enhances Rapamycin's growth inhibitory effect by inhibition of SCF Met30 .
    SMER3
  • HY-10218R
    Everolimus (Standard)

    RAD001 (Standard); SDZ-RAD (Standard)

    		 Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial Cancer
    Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus (Standard)
  • HY-137978
    Ezurpimtrostat
    3 Publications Verification

    GNS561

    		 SARS-CoV IFNAR Autophagy Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
    Ezurpimtrostat
  • HY-122402
    Umirolimus

    		Bacterial Inflammation/Immunology
    Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used agent-eluting stent (DES) applications .
    Umirolimus
  • HY-128340
    Autogramin-2

    		Autophagy Cancer
    Autogramin-2 potently inhibits autophagy induced by either starvation (IC50=0.27 μM) or mTORC1 inhibition (Rapamycin; IC50=0.14 μM) .
    Autogramin-2
  • HY-128339
    Autogramin-1

    		Autophagy Cancer
    Autogramin-1 potently inhibits autophagy induced by either starvation (IC50=0.17 μM) or mTORC1 inhibition (Rapamycin; IC50=0.44 μM) .
    Autogramin-1
  • HY-106345
    ILS-920

    		FKBP Calcium Channel Neurological Disease Inflammation/Immunology
    ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12 .
    ILS-920
  • HY-136583
    28-Epirapamycin

    		Drug Metabolite Others
    28-Epirapamycin is an impurity of Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells .
    28-Epirapamycin
  • HY-124726
    Aumitin

    		Autophagy Neurological Disease Cancer
    Aumitin is a diaminopyrimidine-based autophagy inhibitor which inhibits mitochondrial respiration by targeting complex I. Aumitin inhibits starvation- and rapamycin induced autophagy dose dependently with IC50s of 0.12 μM and 0.24 μM, respectively .
    Aumitin
  • HY-19555
    Seco Rapamycin

    Secorapamycin A

    		 Drug Metabolite Others
    Seco Rapamycin (Secorapamycin A) is the ring-opened product of Rapamycin. Seco-rapamycin is reported not to affect the mTOR function .
    Seco Rapamycin
  • HY-141805
    MHY-1685

    		mTOR Cancer
    MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.
    MHY-1685
  • HY-12652
    AZD3147
    1 Publications Verification

    		 mTOR Cancer
    AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K .
    AZD3147
  • HY-161509
    PT-88

    		mTOR Cancer
    PT-88 is a highly selective inhibitor of mTOR (Mammalian target of rapamycin) (IC50=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of mTOR protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of mTOR in tumorigenesis and development, especially in the study of breast cancer .
    PT-88
  • HY-153511
    Rapamycin analog-2

    		Drug Derivative Cancer
    Rapamycin analog-2 (compound A) is a Rapamycin analog .
    Rapamycin analog-2
  • HY-180482
    41-O-Demethylrapamycin

    		Drug Metabolite Others
    41-O-Demethylrapamycin is a metabolite of Rapamycin (HY-10219) produced by Bacillus megaterium .
    41-O-Demethylrapamycin
  • HY-142003
    27-O-Demethylrapamycin

    		Fungal Infection
    27-O-Demethylrapamycin, a Rapamycin (HY-10219) derivative, is an antifungal agent. 27-O-Demethylrapamycin inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum .
    27-O-Demethylrapamycin
  • HY-135445
    Prolylrapamycin

    21-Norrapamycin

    		 Fungal Infection
    Prolylrapamycin (21-Norrapamycin) is the derivative of Rapamycin (HY-10219). Prolylrapamycin exhibits antifungal activity, that inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum with MIC of 0.125-2 μg/mL .
    Prolylrapamycin
  • HY-122402S
    Umirolimus-d5

    		Isotope-Labeled Compounds Bacterial Inflammation/Immunology
    Umirolimus-d5 is the deuterium labeled Umirolimus (HY-122402). Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used agent-eluting stent (DES) applications .
    Umirolimus-d5
  • HY-106979
    Olcorolimus

    SAR-943

    		 Drug Derivative Interleukin Related Inflammation/Immunology
    Olcorolimus (SAR-943) is a Rapamycin (HY-10219) derivative. Olcorolimus can reduce IL-4, IL-5, eosinophil, neutrophil, lymphocyte, cellular fibronectin; lung epithelial cell proliferation and mucus hypersecretory phenotype in Ovalbumin (HY-W250978)-sensitized BALB/c mice. Olcorolimus can be used for the researches of inflammation and immunology, such as asthma .
    Olcorolimus
  • HY-10218S1
    Everolimus-13C2,d4

    RAD001-13C2,d4; SDZ-RAD-13C2,d4

    		 Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis Cancer
    Everolimus- 13C2,d4 (RAD001- 13C2,d4) is 13C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-13C2,d4
  • HY-145931
    CC214-2

    		mTOR Autophagy Cancer
    CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .
    CC214-2
  • HY-N15267
    Ovalitenone

    		FAK Akt mTOR Cancer
    Ovalitenone is a flavonoid compound that can be isolated from the plant Millettia peguensis. It shows no cytotoxic effects on lung cancer H460 and A549 cells, but it significantly inhibits anchorage-independent growth, CSC-like phenotypes, colony formation, and the migration and invasion capabilities of cancer cells. Ovalitenone can significantly reduce the levels of N-cadherin, snail, and slug, while increasing E-cadherin, thus inhibiting the EMT pathway. Additionally, Ovalitenone suppresses the signaling pathways regulated by focal adhesion kinase (FAK), ATP-dependent tyrosine kinase (AKT), mammalian target of rapamycin (mTOR), and cell division cycle 42 (Cdc42) .
    Ovalitenone
  • HY-133770
    Seco Rapamycin ethyl ester

    		Drug Metabolite Others
    Seco Rapamycin ethyl ester is an open-ring metabolite of Rapamycin derivative. Seco-rapamycin is reported not to affect the mTOR function .
    Seco Rapamycin ethyl ester
  • HY-132003
    Wortmannin-Rapamycin Conjugate 1

    		Akt Cancer
    Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .
    Wortmannin-Rapamycin Conjugate 1
  • HY-W765245
    Rapamycin-13C,d3-1

    Sirolimus-13C,d3-1; AY-22989-13C,d3-1

    		 Isotope-Labeled Compounds Fungal mTOR Bacterial Autophagy Endogenous Metabolite FKBP Antibiotic Cancer
    Rapamycin- 13C,d3-1 (Sirolimus- 13C,d3-1) is the deuterium labeled and 13C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3-1
  • HY-139085A
    XL388-C2-amide-PEG9-NH2 hydrochloride

    		Drug Intermediate Cancer
    XL388-C2-amide-PEG9-NH2 hydrochloride is an intermediate used in the synthesis of C26-linked Rapamycin analog .
    XL388-C2-amide-PEG9-NH2 hydrochloride
  • HY-139085B
    XL388-C2-amide-PEG9-NH2 TFA

    		Drug Intermediate Cancer
    XL388-C2-amide-PEG9-NH2 TFA is an intermediate used in the synthesis of C26-linked Rapamycin analog .
    XL388-C2-amide-PEG9-NH2 TFA
  • HY-185200
    Rapamycin 42-hemisuccinate

    		Drug Derivative Others
    Rapamycin 42-hemisuccinate is a Rapamycin (HY-10219) derivative used in the synthesis of sterolated Rapamycin liposomes .
    Rapamycin 42-hemisuccinate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: